221 related articles for article (PubMed ID: 35867837)
21. Comparison of Chlorantraniliprole and Flubendiamide Activity Toward Wild-Type and Malignant Hyperthermia-Susceptible Ryanodine Receptors and Heat Stress Intolerance.
Truong KM; Pessah IN
Toxicol Sci; 2019 Feb; 167(2):509-523. PubMed ID: 30329129
[TBL] [Abstract][Full Text] [Related]
22. Malignant hyperthermia susceptibility arising from altered resting coupling between the skeletal muscle L-type Ca2+ channel and the type 1 ryanodine receptor.
Eltit JM; Bannister RA; Moua O; Altamirano F; Hopkins PM; Pessah IN; Molinski TF; López JR; Beam KG; Allen PD
Proc Natl Acad Sci U S A; 2012 May; 109(20):7923-8. PubMed ID: 22547813
[TBL] [Abstract][Full Text] [Related]
23. Ca2+ signaling in HEK-293 and skeletal muscle cells expressing recombinant ryanodine receptors harboring malignant hyperthermia and central core disease mutations.
Brini M; Manni S; Pierobon N; Du GG; Sharma P; MacLennan DH; Carafoli E
J Biol Chem; 2005 Apr; 280(15):15380-9. PubMed ID: 15689621
[TBL] [Abstract][Full Text] [Related]
24. Ion-pulling simulations provide insights into the mechanisms of channel opening of the skeletal muscle ryanodine receptor.
Mowrey DD; Xu L; Mei Y; Pasek DA; Meissner G; Dokholyan NV
J Biol Chem; 2017 Aug; 292(31):12947-12958. PubMed ID: 28584051
[TBL] [Abstract][Full Text] [Related]
25. Malignant hyperthermia in Japan: mutation screening of the entire ryanodine receptor type 1 gene coding region by direct sequencing.
Ibarra M CA; Wu S; Murayama K; Minami N; Ichihara Y; Kikuchi H; Noguchi S; Hayashi YK; Ochiai R; Nishino I
Anesthesiology; 2006 Jun; 104(6):1146-54. PubMed ID: 16732084
[TBL] [Abstract][Full Text] [Related]
26. Pathological conformations of disease mutant Ryanodine Receptors revealed by cryo-EM.
Woll KA; Haji-Ghassemi O; Van Petegem F
Nat Commun; 2021 Feb; 12(1):807. PubMed ID: 33547325
[TBL] [Abstract][Full Text] [Related]
27. Mutations in RYR1 in malignant hyperthermia and central core disease.
Robinson R; Carpenter D; Shaw MA; Halsall J; Hopkins P
Hum Mutat; 2006 Oct; 27(10):977-89. PubMed ID: 16917943
[TBL] [Abstract][Full Text] [Related]
28. Dynamic alterations in myoplasmic Ca2+ in malignant hyperthermia and central core disease.
Lyfenko AD; Goonasekera SA; Dirksen RT
Biochem Biophys Res Commun; 2004 Oct; 322(4):1256-66. PubMed ID: 15336973
[TBL] [Abstract][Full Text] [Related]
29. Impaired interaction between skeletal ryanodine receptors in malignant hyperthermia.
Liang X; Chen K; Fruen B; Hu J; Ma J; Hu X; Parness J
Integr Biol (Camb); 2009 Sep; 1(8-9):533-9. PubMed ID: 20023768
[TBL] [Abstract][Full Text] [Related]
30. Muscle weakness in Ryr1I4895T/WT knock-in mice as a result of reduced ryanodine receptor Ca2+ ion permeation and release from the sarcoplasmic reticulum.
Loy RE; Orynbayev M; Xu L; Andronache Z; Apostol S; Zvaritch E; MacLennan DH; Meissner G; Melzer W; Dirksen RT
J Gen Physiol; 2011 Jan; 137(1):43-57. PubMed ID: 21149547
[TBL] [Abstract][Full Text] [Related]
31. Functional Characterization of C-terminal Ryanodine Receptor 1 Variants Associated with Central Core Disease or Malignant Hyperthermia.
Parker R; Schiemann AH; Langton E; Bulger T; Pollock N; Bjorksten A; Gillies R; Hutchinson D; Roxburgh R; Stowell KM
J Neuromuscul Dis; 2017; 4(2):147-158. PubMed ID: 28527222
[TBL] [Abstract][Full Text] [Related]
32. Strenuous exercise triggers a life-threatening response in mice susceptible to malignant hyperthermia.
Michelucci A; Paolini C; Boncompagni S; Canato M; Reggiani C; Protasi F
FASEB J; 2017 Aug; 31(8):3649-3662. PubMed ID: 28465322
[TBL] [Abstract][Full Text] [Related]
33. [Genetic of diseases by abnormal functioning of the skeletal muscle-calcium releasing complex].
Lunardi J; Monnier N
Rev Neurol (Paris); 2004 May; 160(5 Pt 2):S70-7. PubMed ID: 15269663
[TBL] [Abstract][Full Text] [Related]
34. Clinical and functional effects of a deletion in a COOH-terminal lumenal loop of the skeletal muscle ryanodine receptor.
Zorzato F; Yamaguchi N; Xu L; Meissner G; Müller CR; Pouliquin P; Muntoni F; Sewry C; Girard T; Treves S
Hum Mol Genet; 2003 Feb; 12(4):379-88. PubMed ID: 12566385
[TBL] [Abstract][Full Text] [Related]
35. Screening of the ryanodine receptor gene in 105 malignant hyperthermia families: novel mutations and concordance with the in vitro contracture test.
Brandt A; Schleithoff L; Jurkat-Rott K; Klingler W; Baur C; Lehmann-Horn F
Hum Mol Genet; 1999 Oct; 8(11):2055-62. PubMed ID: 10484775
[TBL] [Abstract][Full Text] [Related]
36. Lobe-specific calmodulin binding to different ryanodine receptor isoforms.
Lau K; Chan MM; Van Petegem F
Biochemistry; 2014 Feb; 53(5):932-46. PubMed ID: 24447242
[TBL] [Abstract][Full Text] [Related]
37. Single channel properties of heterotetrameric mutant RyR1 ion channels linked to core myopathies.
Xu L; Wang Y; Yamaguchi N; Pasek DA; Meissner G
J Biol Chem; 2008 Mar; 283(10):6321-9. PubMed ID: 18171678
[TBL] [Abstract][Full Text] [Related]
38. Compound RYR1 heterozygosity resulting in a complex phenotype of malignant hyperthermia susceptibility and a core myopathy.
Kraeva N; Heytens L; Jungbluth H; Treves S; Voermans N; Kamsteeg E; Ceuterick-de Groote C; Baets J; Riazi S
Neuromuscul Disord; 2015 Jul; 25(7):567-76. PubMed ID: 25958340
[TBL] [Abstract][Full Text] [Related]
39. Toward decrypting the allosteric mechanism of the ryanodine receptor based on coarse-grained structural and dynamic modeling.
Zheng W
Proteins; 2015 Dec; 83(12):2307-18. PubMed ID: 26492335
[TBL] [Abstract][Full Text] [Related]
40. A novel ryanodine receptor mutation and genotype-phenotype correlation in a large malignant hyperthermia New Zealand Maori pedigree.
Brown RL; Pollock AN; Couchman KG; Hodges M; Hutchinson DO; Waaka R; Lynch P; McCarthy TV; Stowell KM
Hum Mol Genet; 2000 Jun; 9(10):1515-24. PubMed ID: 10888602
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
